Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2

Ying, M., Shao, X., Jing, H., Liu, Y., Qi, X., Cao, J., Chen, Y., Xiang, S., Song, H., Hu, R., Wei, G., Yang, B., He, Q.
American Society of Hematology (ASH)
Published 2018